Effects of liraglutide on reperfusion injury in patients with ST-segment-elevation myocardial infarction

Circulation: Cardiovascular Imaging

Volumn 9, Issue 12, 2016, Pages

  Chen, Wei Ren ^a   Chen, Yun Dai ^a   Tian, Feng ^a   Yang, Na ^a   Cheng, Liu Quan ^a   Hu, Shun Ying ^a   Wang, Jing ^a   Yang, Jun Jie ^a   Wang, Shi Feng ^a   Gu, Xiao Fang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

C reactive protein; glucagon like peptide 1; myocardial infarction; myocardium; reperfusion injury

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LIRAGLUTIDE; MALONALDEHYDE; NITRIC OXIDE; PLACEBO; SUPEROXIDE DISMUTASE; BIOLOGICAL MARKER; PROTECTIVE AGENT;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELUTING STENT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOGLYCEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL SALVAGE INDEX; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ADVERSE EFFECTS; BLOOD; CHINA; DIAGNOSTIC IMAGING; EMERGENCY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; ST ELEVATION MYOCARDIAL INFARCTION; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CHINA; DOUBLE-BLIND METHOD; EMERGENCIES; FEMALE; HUMANS; LIRAGLUTIDE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION; PROTECTIVE AGENTS; ST ELEVATION MYOCARDIAL INFARCTION; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 85007090126     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.116.005146     Document Type: Article

References (40)

1. Keeley EC, Boura JA, Grines CL, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003 361 13 20. doi: 10.1016/S0140-6736(03)12113-7.
2. Yellon DM, Hausenloy DJ, Myocardial reperfusion injury. N Engl J Med 2007 357 1121 1135. doi: 10.1056/NEJMra071667.
3. Gersh BJ, Stone GW, White HD, Holmes DR Jr., Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 2005 293 979 986. doi: 10.1001/jama.293.8.979.
4. Muller O, Trana C, Eeckhout E, Myocardial no-reflow treatment. Curr Vasc Pharmacol 2013 11 278 285
5. Aronson D, Hammerman H, Kapeliovich MR, Suleiman A, Agmon Y, Beyar R, Markiewicz W, Suleiman M, Fasting glucose in acute myocardial infarction: incremental value for long-Term mortality and relationship with left ventricular systolic function. Diabetes Care 2007 30 960 966. doi: 10.2337/dc06-1735.
6. Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S, Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 2013 36 2346 2350. doi: 10.2337/dc12-2469.
7. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE, Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009 53 501 510. doi: 10.1016/j.jacc.2008.10.033.
8. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ, GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009 58 975 983. doi: 10.2337/db08-1193.
9. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, Jørgensen E, Helqvist S, Saunamäki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Køber L, Treiman M, Holst JJ, Engstrøm T, Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012 33 1491 1499. doi: 10.1093/eurheartj/ehr309.
10. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS, Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013 33 2252 2260. doi: 10.1161/ATVBAHA.113.301586.
11. Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, Yang JJ, Wang ZF, Tian F, Ning QX, Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 2015 170 845 854. doi: 10.1016/j.ahj.2015.07.014.
12. Reffelmann T, Hale SL, Li G, Kloner RA, Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2002 282 H766 H772. doi: 10.1152/ajpheart.00767.2001.
13. Ganz W, The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985 313 1018. doi: 10.1056/NEJM198510173131611.
14. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F, Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998 97 2302 2306
15. Niccoli G, Burzotta F, Galiuto L, Crea F, Myocardial no-reflow in humans. J Am Coll Cardiol 2009 54 281 292. doi: 10.1016/j.jacc.2009.03.054.
16. Workgroup on Hypoglycemia, American Diabetes Association Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005 28 1245 1249
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 150 604 612
18. Best PJ, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf RM, Cardiovascular disease and chronic kidney disease: insights and an update. Am Heart J 2004 148 230 242. doi: 10.1016/j.ahj.2004.04.011.
19. Miller WL, Wright RS, Grill JP, Kopecky SL, Improved survival after acute myocardial infarction in patients with advanced Killip class. Clin Cardiol 2000 23 751 758
20. Parks M, Rosebraugh C, Weighing risks and benefits of liraglutide-The FDA's review of a new antidiabetic therapy. N Engl J Med 2010 362 774 777. doi: 10.1056/NEJMp1001578.
21. Carlsson M, Ubachs JF, Hedström E, Heiberg E, Jovinge S, Arheden H, Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging 2009 2 569 576. doi: 10.1016/j.jcmg.2008.11.018.
22. Heiberg E, Ugander M, Engblom H, Götberg M, Olivecrona GK, Erlinge D, Arheden H, Automated quantification of myocardial infarction from MR images by accounting for partial volume effects: animal, phantom, and human study. Radiology 2008 246 581 588. doi: 10.1148/radiol.2461062164.
23. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM, The use of contrast-enhanced magnetic resonance Imaging to identify reversible myocardial dysfunction. N Engl J Med 2000 343 1445 1453. doi: 10.1056/NEJM200011163432003.
24. Chen WR, Tian F, Chen YD, Wang J, Yang JJ, Wang ZF, Da Wang J, Ning QX, Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol 2016 208 109 114
25. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H, Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010 55 2470 2479. doi: 10.1016/j.jacc.2010.01.049.
26. Wichmann J, Ketzel M, Ellermann T, Loft S, Apparent temperature and acute myocardial infarction hospital admissions in Copenhagen, Denmark: a case-crossover study. Environ Health 2012 11 19. doi: 10.1186/1476-069X-11-19.
27. Jiang L, Krumholz HM, Li X, Li J, Hu S, Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system. Lancet 2015 386 1493 1505. doi: 10.1016/S0140-6736(15)00343-8.
28. Song L, Yan H, Zhao H, Wang J, Chi Y, Wu Z, Zheng B, Wang S, Peng H, Liu C, Zhou P, Improvement in door-To-balloon times in patients with ST-elevation myocardial infarction at a large urban teaching hospital in China. Int J Cardiol 2011 153 81 82. doi: 10.1016/j.ijcard.2011.08.068.
29. Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M, Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009 9 31. doi: 10.1186/1471-2261-9-31.
30. Bernink FJ, Timmers L, Diamant M, Scholte M, Beek AM, Kamp O, Marques KM, Denham RN, Chen WJ, Doevendans PA, van Rossum AC, van Royen N, Horrevoets AJ, Appelman Y, Effect of additional treatment with EXenatide in patients with an acute myocardial infarction: The EXAMI study. Int J Cardiol 2013 167 289 290. doi: 10.1016/j.ijcard.2012.09.204.
31. Fernández-Jiménez R, Sánchez-González J, Agüero J, García-Prieto J, López-Martín GJ, García-Ruiz JM, Molina-Iracheta A, Rosselló X, Fernández-Friera L, Pizarro G, García-Álvarez A, Dall'Armellina E, Macaya C, Choudhury RP, Fuster V, Ibáñez B, Myocardial edema after ischemia/reperfusion is not stable and follows a bimodal pattern: Imaging and histological tissue characterization. J Am Coll Cardiol 2015 65 315 323. doi: 10.1016/j.jacc.2014.11.004.
32. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM, National Heart Lung and Blood Institute, National Institutes of Health New horizons in cardioprotection: recommendations from the 2010 National Heart Lung and Blood Institute Workshop. Circulation 2011 124 1172 1179. doi: 10.1161/CIRCULATIONAHA.111.032698.
33. Undas A, Wiek I, Stêpien E, Zmudka K, Tracz W, Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 2008 31 1590 1595. doi: 10.2337/dc08-0282.
34. Park JY, Takahara N, Gabriele A, Chou E, Naruse K, Suzuma K, Yamauchi T, Ha SW, Meier M, Rhodes CJ, King GL, Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000 49 1239 1248
35. Villanueva-Peñacarrillo ML, Puente J, Redondo A, Clemente F, Valverde I, Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine 2001 15 241 248. doi: 10.1385/ENDO:15:2:241.
36. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP, Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006 317 1106 1113. doi: 10.1124/jpet.106.100982.
37. Bekkers SC, Yazdani SK, Virmani R, Waltenberger J, Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010 55 1649 1660. doi: 10.1016/j.jacc.2009.12.037.
38. Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF, Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011 43 300 305. doi: 10.1055/s-0031-1271777.
39. Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K, Hayashi T, A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010 53 2256 2263. doi: 10.1007/s00125-010-1831-8.
40. Hamshere S, Jones DA, Pellaton C, Longchamp D, Burchell T, Mohiddin S, Moon JC, Kastrup J, Locca D, Petersen SE, Westwood M, Mathur A, Cardiovascular magnetic resonance Imaging of myocardial oedema following acute myocardial infarction: Is whole heart coverage necessary? J Cardiovasc Magn Reson 2016 18 7. doi: 10.1186/s12968-016-0226-5.